Follistatin releases muscle's own brake on growth. Placing it into one muscle reliably makes that muscle bigger, yet not reliably stronger, and the manufacturer stopped its programme for that reason. No licensed product exists anywhere, nearly half the material sold online is not follistatin, and viral gene transfer cannot be undone. (Full Review)

Protocol

Intramuscular gene transfer, the trial regimen

3 × 10¹¹ or 6 × 10¹¹ vector genomes per kilogram per leg

Adeno-associated virus serotype 1 carrying FS-344, injected bilaterally into quadriceps as a single administration.

Intramuscular gene transfer, the longevity-clinic regimen

5 × 10¹⁰ or 1 × 10¹¹ vector genomes per kilogram

Adeno-associated virus serotype 9 carrying follistatin, distributed bilaterally across four muscle groups, with rapamycin cover.

Plasmid gene transfer, the alternative approach

Single subcutaneous dose

Non-integrating FS-344 plasmid giving transient expression; repeat dosing is offered rather than a permanent effect.

Time to effect

Muscle volume

3–6 months

Measured at three to six months in every protocol; the engineered protein showed significant gain by six months.

Walking distance

6 months to 1 year

Gene-transfer trials assessed walking distance at six months and one year.

Benefits

High: Increased skeletal muscle volume at the injected site

Low: Muscle fibre hypertrophy and reduced fibrosis after gene transfer; improved walking distance in muscle-wasting disease; muscle strength — conflicted; reduced intramuscular fat — conflicted

Speculative: Whole-body lean mass gain with fat loss; reduced biological age, joint damage and metabolic inflammation — not central to muscle growth

Contraindications

Any cancer history or hereditary cancer syndrome (BRCA1/2, Lynch, Li-Fraumeni) without clearance

Pregnancy, breastfeeding, premenopausal status, or no contraception for six months

Diabetes of any type, fasting glucose ≥126 mg/dL, or haemoglobin A1c ≥6.5%

Chronic kidney disease stage 3–5 (filtration below 60 mL/min/1.73 m²)

Cirrhosis, chronic viral hepatitis, or transaminases above 1.5× normal

Dysferlinopathy (an inherited muscle-wasting disorder)

Heart failure, ejection fraction <50%, prior myocardial infarction or stroke, left ventricular wall ≥15 mm

Prior adeno-associated virus gene therapy, or antibody titre >1:100

Active infection, tuberculosis, hepatitis B or C, or human immunodeficiency virus

Inflammatory myopathy, systemic connective-tissue disease, or prior rhabdomyolysis

Anti-vascular endothelial growth factor agents (bevacizumab, ranibizumab) with a vascular growth factor plasmid

Key Interactions

Immunosuppressants (rapamycin, tacrolimus)

Corticosteroids (prednisone, dexamethasone)

Anticoagulants and antiplatelets (warfarin, clopidogrel)

Statins and other muscle-toxic drugs (simvastatin, colchicine)

Muscle-targeting interventions (resistance training, blood-flow restriction, growth hormone secretagogues such as ipamorelin)

Androgens and anabolic steroids (testosterone, selective androgen receptor modulators)

Incretin mimetics (semaglutide, tirzepatide)

Over-the-counter anti-inflammatories (ibuprofen, aspirin)

Supplements with additive myostatin-pathway claims (epicatechin, sulforaphane)

Supplements that raise creatine kinase (creatine monohydrate, high-dose caffeine)

Risk & Side Effects

High: Injection-site reactions

Medium: Higher circulating follistatin tracks with cardiometabolic disease

Low: Vector immune response and liver injury; misidentified and adulterated grey-market product; vascular and mucosal effects of broad pathway blockade

Speculative: Suppression of follicle-stimulating hormone; tumour-promoting activin blockade; tendon and connective-tissue weakening

Monitoring

Marker	Target	Why
Serum follistatin	Fold-change from baseline; no set target (roughly 1–10 ng/mL)	Confirms the product expressed at all
Fasting insulin	2–5 µIU/mL	Earliest sign of insulin resistance
Haemoglobin A1c	Below 5.3%	Confirms glucose handling has not drifted
Fasting glucose	75–85 mg/dL	Complements insulin for the same signal
Alanine aminotransferase	Below 20 U/L men; below 17 U/L women	Detects vector liver injury while reversible
Creatine kinase	45–200 U/L	Distinguishes muscle injury from soreness
Follicle-stimulating hormone	Men 1.5–8 IU/L; postmenopausal women 25–135 IU/L	Detects activin-axis suppression
Appendicular lean mass index	Men 8.0–9.5 kg/m²; women 6.5–7.5 kg/m²	The actual outcome being purchased
Estimated glomerular filtration rate	Above 90 mL/min/1.73 m²	Higher follistatin tracks with kidney disease
High-sensitivity C-reactive protein	Below 0.5 mg/L	Tracks inflammatory tone under activin blockade
Serum myostatin and activin A	Baseline before dosing	Defines the brake available to release
Adeno-associated virus antibody titre	1:100 or lower	Eligibility test, once before dosing
Leg-press one-repetition maximum and grip strength	Baseline, then tracked	Volume and function tracked separately

Cadence: Baseline before dosing; liver enzymes and blood counts weekly for eight weeks, then at three, six and twelve months with glucose handling, follistatin, hormones and body composition; thereafter every six to twelve months indefinitely.

Qualitative Assessment

Perceived strength at a fixed working weight, as reps at a constant load
Recovery time between hard training sessions
Joint and tendon comfort during loaded movement
Visible limb girth asymmetry after single-muscle injection
Energy, appetite and sleep quality
Nosebleeds, visible small dilated surface vessels, or unexplained bruising

Follistatin for Muscle Growth

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment